IDH2 and leukemia: Reports from leukaemia demonstrate its dependence on elevated levels of D-2HG for oncogenesis and disease maintenance12, 39, and early phase clinical trials of inhibitors against mutant IDH in leukaemia patients demonstrate provisional yet promising results40.